441 related articles for article (PubMed ID: 34639059)
1. The Positive and Negative Immunoregulatory Role of B7 Family: Promising Novel Targets in Gastric Cancer Treatment.
Bolandi N; Derakhshani A; Hemmat N; Baghbanzadeh A; Asadzadeh Z; Afrashteh Nour M; Brunetti O; Bernardini R; Silvestris N; Baradaran B
Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639059
[TBL] [Abstract][Full Text] [Related]
2. The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3.
Janakiram M; Shah UA; Liu W; Zhao A; Schoenberg MP; Zang X
Immunol Rev; 2017 Mar; 276(1):26-39. PubMed ID: 28258693
[TBL] [Abstract][Full Text] [Related]
3. The role of B7 family molecules in hematologic malignancy.
Greaves P; Gribben JG
Blood; 2013 Jan; 121(5):734-44. PubMed ID: 23223433
[TBL] [Abstract][Full Text] [Related]
4. Wide Expression and Significance of Alternative Immune Checkpoint Molecules, B7x and HHLA2, in PD-L1-Negative Human Lung Cancers.
Cheng H; Borczuk A; Janakiram M; Ren X; Lin J; Assal A; Halmos B; Perez-Soler R; Zang X
Clin Cancer Res; 2018 Apr; 24(8):1954-1964. PubMed ID: 29374053
[No Abstract] [Full Text] [Related]
5. Alternative immune checkpoints in immunoregulatory profile of cancer stem cells.
Mortezaee K; Majidpoor J
Heliyon; 2023 Dec; 9(12):e23171. PubMed ID: 38144305
[TBL] [Abstract][Full Text] [Related]
6. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4.
Qin S; Xu L; Yi M; Yu S; Wu K; Luo S
Mol Cancer; 2019 Nov; 18(1):155. PubMed ID: 31690319
[TBL] [Abstract][Full Text] [Related]
7. B7 family protein glycosylation: Promising novel targets in tumor treatment.
Xiao L; Guan X; Xiang M; Wang Q; Long Q; Yue C; Chen L; Liu J; Liao C
Front Immunol; 2022; 13():1088560. PubMed ID: 36561746
[TBL] [Abstract][Full Text] [Related]
8. Blocking PD-1/PD-L1 by an ADCC enhanced anti-B7-H3/PD-1 fusion protein engages immune activation and cytotoxicity.
Xu Y; Xiao Y; Luo C; Liu Q; Wei A; Yang Y; Zhao L; Wang Y
Int Immunopharmacol; 2020 Jul; 84():106584. PubMed ID: 32422527
[TBL] [Abstract][Full Text] [Related]
9. New B7 Family Checkpoints in Human Cancers.
Ni L; Dong C
Mol Cancer Ther; 2017 Jul; 16(7):1203-1211. PubMed ID: 28679835
[TBL] [Abstract][Full Text] [Related]
10. Potential Therapeutic Targets of B7 Family in Colorectal Cancer.
Wang C; Feng H; Cheng X; Liu K; Cai D; Zhao R
Front Immunol; 2020; 11():681. PubMed ID: 32477326
[TBL] [Abstract][Full Text] [Related]
11. B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity.
Yonesaka K; Haratani K; Takamura S; Sakai H; Kato R; Takegawa N; Takahama T; Tanaka K; Hayashi H; Takeda M; Kato S; Maenishi O; Sakai K; Chiba Y; Okabe T; Kudo K; Hasegawa Y; Kaneda H; Yamato M; Hirotani K; Miyazawa M; Nishio K; Nakagawa K
Clin Cancer Res; 2018 Jun; 24(11):2653-2664. PubMed ID: 29530936
[No Abstract] [Full Text] [Related]
12. PD-L1, B7-H3 and VISTA are highly expressed in gestational trophoblastic neoplasia.
Zong L; Zhang M; Wang W; Wan X; Yang J; Xiang Y
Histopathology; 2019 Sep; 75(3):421-430. PubMed ID: 31013360
[TBL] [Abstract][Full Text] [Related]
13. Mifepristone inhibited the expression of B7-H2, B7-H3, B7-H4 and PD-L2 in adenomyosis.
Qin X; Sun W; Wang C; Li M; Zhao X; Li C; Zhang H
Reprod Biol Endocrinol; 2021 Jul; 19(1):114. PubMed ID: 34289871
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance and correlation of PD-L1, B7-H3, B7-H4, and TILs in pancreatic cancer.
Yang J; Tian Z; Gao H; Xiong F; Cao C; Yu J; Shi W; Zhan Q; Yang C
BMC Cancer; 2022 May; 22(1):584. PubMed ID: 35624419
[TBL] [Abstract][Full Text] [Related]
15. Higher preoperative serum levels of PD-L1 and B7-H4 are associated with invasive and metastatic potential and predictable for poor response to VEGF-targeted therapy and unfavorable prognosis of renal cell carcinoma.
Fukuda T; Kamai T; Masuda A; Nukui A; Abe H; Arai K; Yoshida K
Cancer Med; 2016 Aug; 5(8):1810-20. PubMed ID: 27292320
[TBL] [Abstract][Full Text] [Related]
16. Novel immune scoring dynamic nomograms based on B7-H3, B7-H4, and HHLA2: Potential prediction in survival and immunotherapeutic efficacy for gallbladder cancer.
Lv C; Han S; Wu B; Liang Z; Li Y; Zhang Y; Lang Q; Zhong C; Fu L; Yu Y; Xu F; Tian Y
Front Immunol; 2022; 13():984172. PubMed ID: 36159808
[TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint therapy in liver cancer.
Xu F; Jin T; Zhu Y; Dai C
J Exp Clin Cancer Res; 2018 May; 37(1):110. PubMed ID: 29843754
[TBL] [Abstract][Full Text] [Related]
18. B7x-from bench to bedside.
Kaur G; Janakiram M
ESMO Open; 2019; 4(5):e000554. PubMed ID: 31555486
[TBL] [Abstract][Full Text] [Related]
19. Targeting the B7 family of co-stimulatory molecules: successes and challenges.
Podojil JR; Miller SD
BioDrugs; 2013 Feb; 27(1):1-13. PubMed ID: 23329394
[TBL] [Abstract][Full Text] [Related]
20. The Regulatory Cross-Talk between microRNAs and Novel Members of the B7 Family in Human Diseases: A Scoping Review.
Ahangar NK; Hemmat N; Khalaj-Kondori M; Shadbad MA; Sabaie H; Mokhtarzadeh A; Alizadeh N; Derakhshani A; Baghbanzadeh A; Dolatkhah K; Silvestris N; Baradaran B
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33800752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
